Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com


Dallas, Texas (PRWEB) April 27, 2015

The report Essential Thrombocythemia Pipeline Review, H1 2015 provides comparative analysis on the therapeutic development for Essential Thrombocythemia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Essential Thrombocythemia with 26 market data tables and 14 figures, spread across 85 pages is available at http://www.rnrmarketresearch.com/essential-thrombocythemia-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. Companies discussed in this Essential Thrombocythemia Pipeline Review, H1 2015 report include Aop Orphan Pharmaceuticals AG, Biogenomics Limited, Galena Biopharma, Inc., Gilead Sciences, Inc.

Incyte Corporation, Italfarmaco S.p.A., Novartis AG, Onconova Therapeutics, Inc. and PharmaEssentia Corporation

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are anagrelide hydrochloride CR, erismodegib, givinostat, interferon alfa-2b (recombinant), momelotinib, peginterferon alfa-2b, rigosertib sodium, ruxolitinib phosphate and Small Molecules to Inhibit JAK for Oncology and Hematological Disorders. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365348 . (This is a premium report priced at US$ 2000 for a single user License.)

Featured News & Press Releases cover by this report include: Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 80, Feb 13, 2013: Novartis’s Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 80, May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 81, Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 82 and May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 83.

List of Tables

Number of Products under Development for Essential Thrombocythemia, H1 2015 8

Number of Products under Development for Essential Thrombocythemia – Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Essential Thrombocythemia – Pipeline by Aop Orphan Pharmaceuticals AG, H1 2015 17

Essential Thrombocythemia – Pipeline by Biogenomics Limited, H1 2015 18

Essential Thrombocythemia – Pipeline by Galena Biopharma, Inc., H1 2015 19

Essential Thrombocythemia – Pipeline by Gilead Sciences, Inc., H1 2015 20

Essential Thrombocythemia – Pipeline by Incyte Corporation, H1 2015 21

Essential Thrombocythemia – Pipeline by Italfarmaco S.p.A., H1 2015 22

Essential Thrombocythemia – Pipeline by Novartis AG, H1 2015 23

Essential Thrombocythemia – Pipeline by Onconova Therapeutics, Inc., H1 2015 24

Essential Thrombocythemia – Pipeline by PharmaEssentia Corporation, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Essential Thrombocythemia Therapeutics – Recent Pipeline Updates, H1 2015 58

Essential Thrombocythemia – Dormant Projects, H1 2015 78

Essential Thrombocythemia – Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Essential Thrombocythemia, H1 2015 8

Number of Products under Development for Essential Thrombocythemia – Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Explore more reports on Hematology Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.







Leave a Reply